One of the deadliest forms of cancer today is pancreatic cancer because it's not diagnosed easily, and it usually starts to show itself once the cancer has reached its last stages. To make matters worse, the treatment for cancer is limited.
The good news? Scientists have developed a tiny device that can deliver drugs directly to the pancreatic tumor, which can decrease its size. Then, another team of researchers discovered a molecule that targets and kills cancer cells.
A New Protein
The latest research seems to be even more promising; researchers from Cold Spring Harbor Laboratory (CSHL) in New York were able to identify a protein that kickstarts and accelerates the formation of tumors in the pancreas.
The researchers explored the role of RNA splicing, which is a genetic process that occurs before protein production in pancreatic cancer. They called the protein SRSF1, which regulates the process of RNA splicing. High levels of the protein showed inflammation, which is also known as pancreatitis.
The SRSF1 in the body should only be at a specific level, and this can be done via a range of genes and proteins that work together. However, there are many factors that affect this, which results in an irregular process that leads to tumors in the pancreas.
The scientists conducted their study in an animal model and found the protein to return to normal levels in which the small versions or tumors stopped growing, according to a press release.
Read also: Cancer Patients Who Choose To Die At Home Tend To Live Longer
Sparking Hope
The discovery of the protein SRSF1 and its role in pancreatic cancer could lead to new treatments and therapies for patients. By regulating the levels of this protein, it may be possible to prevent the formation of tumors or even stop their growth. However, further research is needed to fully understand the mechanisms involved and develop effective treatments.
Pancreatic cancer is a deadly disease that has limited treatment options, and it often goes undetected until its later stages. This makes finding new ways to treat or prevent the disease all the more urgent. The discovery of SRSF1 as a key player in pancreatic cancer could lead to novel therapies that target this protein.
In addition to regulating RNA splicing, SRSF1 has been linked with other cellular processes, such as cell growth and survival. Thus, targeting this protein may have broader implications beyond just treating pancreatic cancer.
Moreover, understanding how irregular RNA splicing contributes to tumor formation could shed light on similar mechanisms in other types of cancers. This knowledge can be applied to developing treatments for various forms of cancer.
While further research is necessary before any potential treatments based on these findings can be developed and tested in humans, researchers are optimistic about the possibilities ahead thanks to their discoveries regarding SRSF1's role in pancreatic cancer development.
Related article: Cancer-Causing Compounds Not Risk to Average Person Says EU Study Noted SFA
